Significant correlation between plasma proteome profile and pain intensity, sensitivity, and psychological distress in women with fibromyalgia

Karin Wåhlén1, Malin Ernberg2, Eva Kosek3, Kaisa Mannerkorpi4, Björn Gerdle1,5 & Bijar Ghafouri1,5

Fibromyalgia (FM) is a chronic complex pain condition with an estimated prevalence of about 1–4% in the general population.1–3 Key cardinal characteristics in FM are generalized widespread pain and hyperalgesia/allodynia, and symptoms as fatigue, depression, anxiety, sleep problems, cognitive impairments, headache, and muscle tenderness are often present. FM is more common in women (approximately six out of ten patients in unbiased studies), where factors such as increasing age and obesity could play a role.1,5–7 Over the past three decades the American College of Rheumatology (ACR) have released several criteria to assess a clinical diagnosis of FM. In the 1990 version, diagnosis is based on semi-objective examination of hyperalgesia (tender points), presence of generalized pain, in combination with evaluation of anamnestic reports. In the criteria from 2010/2011 and 2016, diagnosis is based upon physician-based questionnaires defining widespread pain and symptom severity; a medical examination of hyperalgesia is no longer needed. Generally, there is a lack of mechanism-based diagnoses within FM and other chronic pain conditions since the pathophysiological and molecular mechanisms behind it are insufficiently elucidated. Hence, there is a need for valid objective biological markers (biomarkers) not only for diagnosis, but for evaluation of treatments and other interventions.

There is increasing evidence that not only central mechanisms are essential for the presentation and the maintenance of the clinical picture in FM patients. Hence, in addition to the studies reporting central alterations...
score plot showed a clear separation between FM and CON (Fig. 1a), and the loading plot showed 18 unique
explained variation, predictivity, and a significant CV-ANOVA (R2 = 0.61, Q2 = 0.36, CV-ANOVA: < 0.05). A
significant OPLS-DA model had one predictive component and one orthogonal component, which showed a high
separation of patients and controls compared in an orthogonal partial least square—discriminant analysis (OPLS-DA) model (Fig. 1a, b). The sig-
nificant results were confirmed by an empirical check for outliers, and by permutation test (999 permutations) providing
robustness. No differences were found in the number of proteins between FM and CON (Fig. 1a). The OPLS-DA model
was significant (R2 = 0.61, Q2 = 0.36, CV-ANOVA: < 0.001) and explained 61% of the total variance.

(e.g., anatomical and functional changes in the brain, activation of glia cells, opioidergic dysregulation, impaired
top-down modulation and nociception-driven amplification of neural signalling), several studies have shown
systemic and peripheral changes in FM, e.g., regarding cytokine profile, inflammatory lipids, alteration of
different metabolites and changes of the gut microbiota and altered protein changes in muscle. So far, no clinically validated biomarkers for FM have been established. Body fluids such as plasma, saliva, urine, and cerebrospinal fluid (CSF) have been investigated for the study of protein biomarkers in different chronic pain conditions e.g., neuropathic pain, chronic widespread pain (CWP), and fibromyalgia. Metabolic and proteomic analysis of these biofluids, especially the metabolomics of blood, urine, and gut microbiome composition, as well as the protein profile of plasma and CSF, have been reported to be able to discriminate FM/CWP patients from healthy controls. Further, most reported biomarker studies in FM/CWP point towards an inflammatory state/response in these chronic pain patients. However, the results are not unequivocally consistent; in one of the largest studies of FM (n = 39), only moderate differences were found in the CSF proteome between patients and controls.

Table 1. Background data. FM Fibromyalgia, CON controls, BMI body mass index, VAS visual analogue scale, PPT pressure pain thresholds, FIQ fibromyalgia impact questionnaire, HADS Hospital Anxiety and Depression Scale. * Mann Whitney-U statistical test was used for all variables.

| Variables                  | CON (n = 31) | FM (n = 30) | p value* |
|----------------------------|--------------|-------------|----------|
| Age (years)                | 57 (9)       | 54 (13)     | 0.366    |
| BMI (kg/m²)                | 24 (3)       | 26 (6)      | < 0.05   |
| FM duration (years)        | –            | 12 (14)     | –        |
| Tender points (number)     | –            | 16 (2)      | –        |
| Pain intensity (VAS)       | 0 (2)        | 50 (36)     | < 0.001  |
| PPT all sites (kPa)        | 340 (146)    | 175 (88)    | < 0.001  |
| FIQ total                  | 2 (8)        | 58 (24)     | < 0.001  |
| HADS total (psychological distress) | 3 (5) | 13 (14) | < 0.001 |

The plasma proteome has been of large interest when investigating biomarkers in different diseases. The
advantages of studying plasma for biomarker discovery are that it is easy to access, low-invasive to the subject,
and rich in proteins. Furthermore, the blood is in direct contact with all surrounding tissue and therefore has
the potential to reflect both peripheral tissue and systemic changes. In a preliminary study of the serum proteome
in FM, Ruggiero et al. found upregulated levels of the proteins alpha-1-antitrypsin, transthyretin, and retinol-
binding protein 4 compared to healthy controls. More recently, Ramíres-Tejero et al. explored the plasma
proteome in FM compared to controls and reported significant changes in several proteins involved in inflam-
mation, suggesting haptoglobin and fibrinogen as potential biomarkers for FM. Both these studies are in line
with our previous proteomic study of plasma in CWP patients mainly FM compared to healthy controls and its
correlation to pain intensity and psychological distress. However, these studies were performed on small
cohorts of patients, and the validity of the identified protein changes needs to be investigated in a larger cohort.

Due to the limited numbers of studies exploring the plasma proteome profile in FM, including their low
sample sizes, more studies are warranted to cover the existing knowledge gap concerning the activated molecular
mechanisms in FM. This also includes efforts to identify potential biomarkers for FM, including aspects of the
clinical presentation. Therefore, the primary aim of this study was to investigate the plasma proteome profile in
FM patients compared to healthy subjects (CON). The secondary aim was to investigate if plasma protein patterns
correlate with the clinical variables pain intensity, pain sensitivity, and psychological distress.

Results
Background data. No differences in age were found between the groups. However, body mass index (BMI)
was significantly higher in FM compared to CON; overweight (i.e., BMI ≥ 25 kg/m²) was present in 18 patients
and eight controls. Pressure pain thresholds (PPT) were significantly lower, while the pain intensity (visual ana-
logue scale, VAS), the scores from the fibromyalgia impact questionnaire (FIQ), and the hospital anxiety and
depression scale (HADS) were significantly higher in FM compared to CON (Table 1).

Proteomics. A total of 381 proteins including different proteoforms were detected and matched in the two-
dimensional gel electrophoresis (2-DE) analysis and used for multivariate modeling. A representative 2-DE gel
of the identified plasma proteins, including mass spectrometry (MS) data from each multivariate data analysis
(MVDA) model is provided in Supplementary Figure S1 and Supplementary Table S1.

MVDA models
Group difference in plasma proteome (FM vs. CON). The plasma proteome from FM and CON was
compared in an orthogonal partial least square—discriminant analysis (OPLS-DA) model (Fig. 1a, b). The sig-
nificant OPLS-DA model had one predictive component and one orthogonal component, which showed a high
explained variation, predictivity, and a significant CV-ANOVA (R² = 0.61, Q² = 0.36, CV-ANOVA: p < 0.001). The
score plot showed a clear separation between FM and CON (Fig. 1a), and the loading plot showed 18 unique
proteins, expressed as 35 proteoforms, that were significantly altered (variable influence on projection (VIP) > 1) and were able to discriminate between FM and CON (Fig. 1b). Differences in the optical density of quantified proteins between the two groups are shown in Fig. 1c. The proteoforms with highest VIP values (VIP > 1.5), which contributed most to the separation between the two groups were upregulated proteoforms of serotransferrin (spot number 7619), alpha-2-antiplasmin (spot number 3403), haptoglobin (spot number 4107), and downregulated proteoforms of Ig kappa chain C region (spot number 9010), complement C4-B (fragment) (spot number 8101), and fibrinogen alpha chain (fragment) (spot number 9106) (Table 2). Out of the 35 significant proteoforms, 11 were positively associated with the FM group, all upregulated proteoforms of serotransferrin (spot number 7619 and 7621), alpha-2-antiplasmin (spot number 3403), haptoglobin (spot number 4107 and 4103), fibrinogen alpha chain (8510), fibrinogen beta chain (spot number 7203), complement C4-B (fragment) (spot number 7101), complement C3 beta chain (spot number 7403), beta-2-glycoprotein 1 (spot number 7206), and gelsolin (spot number 6606) (Fig. 1b, c, Table 2).

Pathway analysis of proteins associated with group differences FM and CON. To investigate functional protein interactions, the discriminant proteins (Fig. 1, Table 2) were analyzed using Search Tool for Retrieval of Interacting Genes/Proteins (STRING) pathway analysis (Fig. 2). Sixteen of 18 proteins were included in the identified network. Immunoglobulin kappa chain C region and the unidentified protein were not identified by the search engine. The colored lines represent different types of evidence of the associated interaction between the proteins in the network, e.g., complement C3 is closely interacted with the other complement proteins, but also with fibrinogen alpha chain, serotransferrin, kininogen-1, and haptoglobin. Gelsolin is located further away in the network and has indirect interactions with the other complement proteins through complement C3, haptoglobin, serotransferrin, and alpha-2-macroglobulin. In this enriched network, several biological processes were identified, i.e., immune response (FDR = 1.23E-06), inflammatory response (FDR = 0.00026), blood coagulation (FDR = 1.58E-06), and protein metabolic processes (FDR = 8.39E-06). The proteins positively associated with FM were proteins belonging to immune and inflammatory processes.

Pain intensity in FM. In the OPLS model of pain intensity (VAS), 11 unique proteins, expressed as 13 proteoforms were multivariate correlated with pain intensity in FM (Fig. 3). The significant model had one principal component and showed a good explained variation, predictivity, and a significant CV-ANOVA ($R^2 = 0.56$, $Q^2 = 0.45$, CV-ANOVA; $p < 0.001$). The score plot showed a within-group separation based on pain intensity in FM. The loading plot showed four proteoforms that were associated with mild pain intensity (VAS < 45 mm), seven proteoforms that were associated with moderate pain intensity (VAS 45–74 mm), and two proteoforms that were associated with severe pain intensity (VAS > 75 mm). The nine proteoforms that were associated with severe and moderate pain intensity were one upregulated proteoform of alpha-2-macroglobulin (spot num-
ber 4808), serotransferrin (spot number 7404), and downregulated proteoform of ceruloplasmin (spot number 3810), haptoglobin beta chain (spot number 5104), antithrombin-III (spot number 3207), hemopexin (spot number 6403), alpha-2-macroglobulin (spot number 5905), immunoglobulin J chain (spot number 1007), and clusterin (spot number 1107) (Fig. 3 and Table 3). Additionally, a correlation analysis of VAS and the significant proteoforms from the OPLS model of VAS was analyzed, which showed 10 of 13 proteoforms had a correlation with pain intensity in FM (Supplementary Figure S2).

Pathway analysis of proteins associated with pain intensity in FM. Based on the result of the OPLS model of pain intensity in FM, a functional protein network analysis was created using STRING analysis (Fig. 4). Eleven proteins were included in the identified network, forming a large cluster. Fibrinogen alpha chain interacted with almost all proteins except for Immunoglobulin J that lacked any functional interaction to the investigated pro-

| Spot number | Protein name                        | Accession number     | VIPpred | p(corr) | Fold change FM versus CON |
|-------------|-------------------------------------|----------------------|---------|---------|---------------------------|
| 9010        | Ig kappa chain C region             | P01834               | 1.92    | −0.56   | 0.40                      |
| 7619        | Serotransferrin                      | P02787               | 1.61    | +0.47   | 1.50                      |
| 3403        | Alpha-2-antiplasmin                  | P08697               | 1.58    | +0.46   | 2.04                      |
| 8101        | Complement C4-B (fragment)           | P0C0L5               | 1.57    | −0.45   | 0.71                      |
| 9106        | Fibrinogen alpha chain (fragment)    | P02671               | 1.57    | −0.45   | 0.27                      |
| 4107        | Haptoglobin                         | P00738               | 1.51    | +0.44   | 1.26                      |
| 8413        | Fibrinogen alpha chain               | P02671               | 1.49    | −0.43   | 0.34                      |
| 7621        | Serotransferrin                      | P02787               | 1.48    | +0.43   | 1.17                      |
| 7101        | Complement C4-B (fragment)           | P0C0L5               | 1.48    | +0.43   | 1.27                      |
| 7203*       | Fibrinogen beta chain                | P02675               | 1.45    | +0.42   | 1.59                      |
| 3502        | Alpha-1B-glycoprotein                | P04217               | 1.43    | −0.41   | 0.87                      |
| 9105        | Fibrinogen alpha chain (fragment)    | P02671               | 1.37    | −0.40   | 0.55                      |
| 8706        | Plasminogen                          | P00747               | 1.37    | −0.40   | 0.84                      |
| 7403        | Complement C3 beta chain             | P01024               | 1.33    | +0.39   | 1.19                      |
| 1404*       | Kininogen-1                          | P01042               | 1.33    | −0.38   | 0.72                      |
| 8701        | Plasminogen                          | P00747               | 1.30    | −0.38   | 0.94                      |
| 2410*       | Alpha-2-antiplasmin                  | P08697               | 1.28    | −0.37   | 0.66                      |
| 4814        | Alpha-2-macroglobulin                | P01023               | 1.28    | −0.37   | 0.41                      |
| 4401        | Alpha-2-antiplasmin                  | P08697               | 1.24    | −0.36   | 0.84                      |
| 9110        | Fibrinogen alpha chain (fragment)    | P02671               | 1.24    | −0.36   | 0.44                      |
| 5602        | Complement C1r subcomponent          | P00736               | 1.17    | −0.34   | 0.85                      |
| 4103        | Haptoglobin                          | P00738               | 1.14    | +0.33   | 1.24                      |
| 8703        | Plasminogen                          | P00747               | 1.12    | −0.33   | 0.91                      |
| 9703        | Plasminogen                          | P00747               | 1.11    | −0.32   | 0.74                      |
| 9007**      | Ig kappa chain C region              | P01834               | 1.11    | −0.32   | 0.62                      |
| 7206        | Beta-2-glycoprotein 1                | P02749               | 1.06    | +0.31   | 1.10                      |
| 8510        | Fibrinogen alpha chain               | P02671               | 1.06    | +0.31   | 1.19                      |
| 9108        | Fibrinogen alpha chain (fragment)    | P02671               | 1.05    | −0.30   | 0.26                      |
| 5903        | Alpha-2-macroglobulin                | P01023               | 1.05    | −0.30   | 0.65                      |
| 2113        | Complement factor I light chain      | P05156               | 1.05    | −0.30   | 0.88                      |
| 6606        | Gelsolin                             | P06396               | 1.03    | +0.30   | 1.01                      |
| 1004        | Apolipoprotein C-III                 | P02656               | 1.01    | −0.29   | 0.33                      |
| 6205        | Unidentified                         | Unknown              | 1.01    | −0.29   | 0.91                      |
| 6726*       | Complement C3b alpha chain           | P01024               | 1.00    | −0.29   | 0.73                      |
| 3728        | Complement C1r subcomponent          | P00736               | 1.00    | −0.29   | 0.74                      |

Table 2. Significant plasma proteins in the OPLS-DA model of FM and CON. Spot numbers refers to equal numbers in Fig. 1b, c and marked proteins spots in supplementary Figure S1 and Table S1. Accession numbers are according to the protein data base UniProt (www.uniprot.org). Variable influence on projections (VIP) indicates the importance of the regressor, the higher value, the more important for the model. A VIP > 1 is considered as a significant protein, and here, only the significant proteins are shown. p(corr) is shown and is the multivariate correlation coefficient of each variable (protein) for the model. FM is coded 1, and CON coded 0. Hence, a positive p(corr) for a variable indicates a positive multivariate correlation versus FM belonging, and a negative p(corr), indicates a negative multivariate correlation with FM. For CON, the relationship is reversed. Please note that fold change is a univariate measure and do not necessarily correspond to p(corr); i.e., a positive fold change (FM > CON), is not automatically equal to a positive p(corr). *Indicates shared proteoform in the model of PPT in FM, **indicated shared proteoform in the model of HADS in FM.
Proteins in the network. In the enriched network, several biological processes were identified, i.e., immune response (FDR = 0.00098), blood coagulation (FDR = 1.43E−05), and protein metabolic process (FDR = 0.00053). Most of the proteins were involved in metabolic and immunity processes.

**Figure 2.** Pathways analysis group differences FM and CON. Investigation of functional protein network from significant plasma proteins that could discriminate between FM and CON. The STRING version 11 was used to create the network analysis (https://string-db.org/). A2M Alpha-2-macroglobulin, GSN Gelsolin, HP Haptoglobin, FGA Fibrinogen alpha chain, FGB Fibrinogen beta chain, APOH Beta-2-glycoprotein 1, PLG Plasminogen, SERPINF2 Alpha-2-antiplasmin, KNG1 Kininogen-1, CFI Complement factor I, A1BG Alpha-1B-glycoprotein, C3 Complement C3, TF Serotransferrin, APOC3 Apolipoprotein C-III, C1R Complement C1r subcomponent, C4B Complement C4-B.

**Figure 3.** Pain intensity and associated plasma proteins in FM. The Score plot (left) shows a within-group separation in the FM group based on pain intensity (visual analogue scale, VAS). The plot shows that FM patients are grouped as having mild (5–44), moderate (45–74), and severe (75–100) pain intensity. The larger the triangle, the higher the pain intensity. The loading plot (right) shows 13 significant proteoforms (VIP > 1) associated with pain intensity. Nine proteoforms were associated with higher pain intensity in FM (VAS > 45). Numbers in the loading plot equals the spot numbers in Table 3 and supplementary Figure S1 and Table S1. The loading and score plots were created in SIMCA P+ (version 15).
Pressure pain thresholds (PPT) in FM. Ten unique proteins expressed as 14 proteoforms were multivariate correlated with PPT in FM according to the significant OPLS model (Fig. 5). The significant model had one predictive and one orthogonal component and showed a good explained variation, predictivity, and significant Table 3. Pain intensity and associated plasma proteins in FM. Plasma proteins with a VIP > 1, associated with pain intensity in the FM group. Spot numbers refers to equal numbers in Fig. 3 and marked proteins spots in supplementary Figure S1 and Table S1. Accession numbers are according to the protein data base UniProt (www.uniprot.org). Variable influence on projections (VIP) indicates the importance of the regressor, the higher value, the more important for the model. A VIP > 1 is considered as a significant protein. p(corr) is shown and is the correlation coefficient of each variable (protein) in the model. A positive p(corr) for a variable indicates a positive multivariate correlation with the Y-variable (pain intensity), and a negative p(corr), indicates a negative multivariate correlation with pain intensity in FM. The median quantified intensity (optical density, OD) from each group is shown in the table as a comparison. As descriptive values, protein fold change in FM compared to CON is reported. Please note that fold change is a univariate measure and do not necessarily correspond to p(corr); i.e., a positive fold change (FM > CON) is not automatically equal to a positive p(corr). The CON group is not included in the OPLS analysis.

| Spot number | Protein name               | Accession number | VIPpred | p(corr) | FM median OD (interquartile range) | CON median OD (interquartile range) | Fold change FM versus CON |
|-------------|----------------------------|------------------|---------|---------|-----------------------------------|------------------------------------|--------------------------|
| 6103        | Fibrinogen beta chain      | P02675           | 1.21    | -0.67   | 465 (173)                         | 449 (200)                          | 1.04                     |
| 8508        | Fibrinogen alpha chain     | P02671           | 1.15    | -0.64   | 383 (266)                         | 382 (343)                          | 1.00                     |
| 8402        | Fibrinogen alpha chain     | P02671           | 1.12    | -0.62   | 275 (292)                         | 245 (185)                          | 1.12                     |
| 6203        | Beta-2-glycoprotein 1      | P02749           | 1.06    | -0.56   | 747 (290)                         | 663 (251)                          | 1.13                     |

Moderate pain intensity (45–74)

| Spot number | Protein name               | Accession number | VIPpred | p(corr) | FM median OD (interquartile range) | CON median OD (interquartile range) | Fold change FM versus CON |
|-------------|----------------------------|------------------|---------|---------|-----------------------------------|------------------------------------|--------------------------|
| 3810        | Ceruloplasmin              | P00450           | 1.31    | +0.72   | 203 (169)                         | 216 (174)                          | 0.94                     |
| 5104        | Haptoglobin beta chain     | P00738           | 1.18    | +0.65   | 112 (394)                         | 226 (349)                          | 0.50                     |
| 3207        | Antithrombin-III           | P01008           | 1.15    | +0.64   | 469 (256)                         | 687 (257)                          | 0.97                     |
| 4808        | Alpha-2-macroglobulin      | P01023           | 1.13    | +0.63   | 392 (421)                         | 320 (829)                          | 1.22                     |
| 7404        | Serotransferrin            | P02787           | 1.13    | +0.63   | 350 (308)                         | 310 (291)                          | 1.13                     |
| 5905        | Alpha-2-macroglobulin      | P01023           | 1.07    | +0.59   | 328 (541)                         | 455 (388)                          | 0.72                     |
| 6403        | Hemopexin                  | P02790           | 1.04    | +0.57   | 1,047 (746)                       | 1,198 (556)                       | 0.87                     |

Severe pain intensity (75–100)

| Spot number | Protein name               | Accession number | VIPpred | p(corr) | FM median OD (interquartile range) | CON median OD (interquartile range) | Fold change FM versus CON |
|-------------|----------------------------|------------------|---------|---------|-----------------------------------|------------------------------------|--------------------------|
| 1007        | Immunoglobulin J chain     | P01591           | 1.13    | +0.62   | 405 (489)                         | 526 (415)                          | 0.77                     |
| 1107        | Clusterin                  | P10909           | 1.01    | +0.56   | 1,546 (645)                       | 1,650 (832)                       | 0.94                     |

Figure 4. Pathway analysis of pain intensity in FM. Protein–protein network analysis of plasma proteins correlated with pain intensity in FM. The STRING version 11 was used to create the network analysis (https://string-db.org/). A2M Alpha-2-macroglobulin, HP Haptoglobin, IGJ Immunoglobulin J chain, FGA Fibrinogen beta chain, FGA Fibrinogen alpha chain, TF Serotransferrin, APOH Beta-2-glycoprotein 1, CP Ceruloplasmin, CLU Clusterin, SERPINC1 Antithrombin-III, HPX Hemopexin.

Pressure pain thresholds (PPT) in FM. Ten unique proteins expressed as 14 proteoforms were multivariate correlated with PPT in FM according to the significant OPLS model (Fig. 5). The significant model had one predictive and one orthogonal component and showed a good explained variation, predictivity, and significant
CV-ANova (R² = 0.83, Q² = 0.52, CV-ANOVA: p < 0.001). A within-group separation in the FM group is seen based on measured PPT and is visualized in the score plot. The loading plot showed five out of 14 proteoforms were associated with very low PPT (< 200 kPa), while nine proteoforms were associated with slightly higher PPT (201–300 kPa). The five proteoforms associated with very low PPT were upregulated proteoforms of angiotensinogen (spot number 1405), alpha-2-HS-glycoprotein (spot number 1317), fibrinogen beta chain (spot number 7203), and one upregulated and one downregulated proteoform of alpha-1-antitrypsin (spot number 1315 and 2310), respectively (Fig. 5 and Table 4). Additionally, a correlation analysis of PPT and the significant proteoforms from the OPLS model of PPT was analyzed, which showed six of 14 proteoforms had a correlation with PPT in FM (Supplementary Figure S3).

Pathway analysis of proteins related to PPT in FM. The significant proteins from the OPLS model of PPT in FM were analyzed to explore the functional protein network using STRING analysis (Fig. 6). Eight of ten proteins were included in the identified network (Ig alpha-2 chain C region and Ig kappa chain C region was not detected) and showed a relatively large cluster with several protein interactions. Kininogen-1 showed interaction with all proteins included in the network, especially with alpha-1-antitrypsin and angiotensinogen. The enriched protein network identified biological processes that were involved in, i.e., inflammatory response (FDR = 1.93E−05), regulation of inflammatory response (FDR = 0.0023), positive regulation of immune response (FDR = 0.0076), and blood coagulation (FDR = 0.0017). Most of the proteins associated with PPT in FM belonged to inflammatory response.

Psychological distress (HADS total) in FM. To assess plasma protein correlations to psychological distress in FM, an OPLS model was applied with the total score of HADS as dependent variable. The obtained significant model had one predictive and one orthogonal component with high explained variation, predictivity, and significant CV-ANova (R² = 0.87, Q² = 0.47, CV-ANOVA: p < 0.01). The score plot shows a within-group separation among FM based on psychological distress (Fig. 7). The loading plot shows 17 unique proteins, expressed as 26 proteoforms that were multivariate correlated with psychological distress in the FM group (Fig. 7). Seventeen proteoforms were associated with normal psychological distress (HADS < 14). One proteoform was associated with mild psychological distress (HADS = 15–20), and eight proteoforms were associated with moderate psychological distress (HADS > 21). The eight proteoforms associated with moderate psychological distress in FM were downregulated proteoforms of alpha-2-HS-glycoprotein (spot number 1203), apolipoprotein A-I (spot number 3010), Ig kappa chain C region (spot number 9007), fibrinogen beta chain (spot number 9409), two proteoforms of fibrinogen alpha chain (spot number 9503 and 9501), and one upregulated proteoform of fibrinogen alpha chain (spot number 8509) (Fig. 7 and Table 5). Additionally, a correlation analysis of HADS and the significant proteoforms from the OPLS model of HADS was analyzed, which showed 17 of 26 proteoforms had a correlation with psychological distress in FM (Supplementary Figure S4).

Pathway analysis psychological distress in FM. The significant proteins from the OPLS model of psychological distress in FM were analyzed to explore functional protein network using STRING analysis. Fourteen of 17 proteins were included in the identified network (Ig kappa chain C region and the two unidentified proteins were not detected) and showed a large cluster with several protein interactions. Almost all proteins interacted with one another in the network, especially fibrinogen alpha chain, fibrinogen beta chain, and alpha-2-antiplasmin. The enriched protein network identified several biological processes, i.e., blood coagulation, fibrin clot formation (FDR = 3.40E−05), immune response (FDR = 8.92E−06), regulation of immune response (FDR = 2.88E−05), acute-phase response (FDR = 3.12E−06), and vitamin transport (FDR = 0.0029). Most of the proteins associated...
Table 4. Pressure pain thresholds (PPT) and associated plasma proteins in FM. Plasma proteins with a VIP > 1 associated with PPT in FM. Spot numbers refers to equal numbers in Fig. 5 and marked proteins spots in supplementary Figure S1 and Table S1. Accession numbers are according to the protein data base UniProt (www.uniprot.org). Variable influence on projections (VIP) indicates the importance of the regressor, the higher value, the more important for the model. A VIP > 1 is considered as a significant protein. p(corr) is shown and is the correlation coefficient of each variable (protein) for the model. A positive p(corr) for a variable indicates a positive multivariate correlation with the Y-variable (PPT), and a negative p(corr), indicates a negative multivariate correlation with PPT in FM. The median quantified intensity (optical density, OD) from each group is shown in the table as a comparison. As descriptive values, protein fold change in FM compared to CON is reported. Please note that fold change is a univariate measure and do not necessarily correspond to p(corr); i.e., a positive fold change (FM > CON) is not automatically equal to a positive p(corr). The CON group is not included in the OPLS analysis. *Indicates shared proteoform with the model of group differences in FM and CON.

| Spot number | Protein name          | Accession number | VIPpred | p(corr)   | FM median OD (interquartile range) | CON median OD (interquartile range) | Fold change FM versus CON |
|-------------|-----------------------|------------------|---------|-----------|-----------------------------------|------------------------------------|---------------------------|
| PPT < 200 kPa |                       |                  |         |           |                                   |                                    |                           |
| 1405        | Angiotensinogen       | P01019           | 1.47    | −0.51     | 877 (796)                         | 806 (606)                          | 1.09                      |
| 7203*       | Fibrinogen beta chain | P02675           | 1.40    | −0.49     | 2,726 (1,121)                     | 1,712 (1,708)                      | 1.59                      |
| 1317        | Alpha-2-HS-glycoprotein | P02765         | 1.20    | −0.42     | 1,812 (2,439)                     | 1,153 (2,251)                      | 1.57                      |
| 1315        | Alpha-1-antitrypsin   | P01009           | 1.03    | −0.36     | 5,329 (2,037)                     | 4,680 (1,740)                      | 1.14                      |
| 2310        | Alpha-1-antitrypsin   | P01009           | 1.02    | −0.35     | 23,970 (5,242)                    | 24,682 (4,898)                     | 0.97                      |
| PPT 201–300 kPa |                   |                  |         |           |                                   |                                    |                           |
| 6404        | Hemopexin            | P02790           | 1.73    | +0.60     | 1,027 (592)                       | 1,091 (494)                        | 0.94                      |
| 6408        | Ig alpha-2 chain C region | P01877       | 1.69    | +0.59     | 1,543 (1,447)                     | 1,957 (1,386)                      | 0.79                      |
| 2410*       | Alpha-2-antiplasmin   | P08697           | 1.66    | +0.58     | 538 (648)                         | 818 (1,446)                        | 0.66                      |
| 6401        | Hemopexin            | P02790           | 1.48    | +0.51     | 1,916 (365)                       | 1,854 (502)                        | 1.03                      |
| 6002        | Ig kappa chain C region | P01834       | 1.18    | +0.41     | 682 (767)                         | 588 (815)                          | 1.16                      |
| 1404*       | Kininogen-1          | P01042           | 1.15    | +0.40     | 339 (204)                         | 468 (280)                          | 0.72                      |
| 2706        | Alpha-1-antitrypsin   | P01009           | 1.11    | +0.39     | 12 (30)                           | 10 (32)                            | 1.22                      |
| 6726*       | Complement C3b alpha chain | P01024          | 1.05    | +0.37     | 185 (226)                         | 252 (116)                          | 0.73                      |
| 2508        | Alpha-2-antiplasmin   | P08697           | 1.03    | +0.36     | 71 (108)                          | 102 (136)                          | 0.69                      |

Figure 6. Pathway analysis of pressure pain thresholds (PPT) in FM. Functional protein network analysis of significant plasma proteins associated with PPT in FM. The STRING version 11 was used to create the network analysis (https://string-db.org). C3 Complement C3, FGB Fibrinogen beta chain, SERPINA1 Alpha-1-antitrypsin, SERPINF2 Alpha-2-antiplasmin, KNG1 Kininogen-1, AGT Angiotensinogen, AHSG Alpha-2-HS-glycoprotein, HPX Hemopexin.
with the highest severity of psychological distress (i.e., moderate) belonged to blood coagulation, fibrin clot formation process (Fig. 8).

Comparison between models, shared proteoforms, and accession numbers. To illustrate shared proteoforms and proteins between the above-presented models Venn diagrams were created. Four proteoforms; kininogen-1 (spot number 1404), alpha-2-antiplasmin (spot number 2410), complement C3b alpha chain (spot number 6726), and fibrinogen beta chain (7203) were significantly altered and shared between the models of group differences in FM vs. CON and PPT in FM (Fig. 9a, these proteoforms are marked in the respective table with *). One proteoform of Ig kappa chain C region (spot number 9007) was shared between the models of group differences in FM vs. CON and HADS in FM (Fig. 9a, this proteoform is marked in the respective table with **).

When comparing protein accession numbers between the models without taking proteoforms into account, several models shared the same type of protein, but not the same proteoforms (i.e., as indicated by spot number), e.g., fibrinogen beta chain was present in all models and hemopexin was present in the models of pain intensity, PPT, and psychological distress in FM (Fig. 9b).

Adjusting for confounding effects on significant proteoforms. The FM group had significantly higher BMI compared to CON. To evaluate if BMI had any confounding effect on significant proteoforms from each MVDA model, additional OPLS models were analyzed. An OPLS model was performed where only the FM group was included in the analysis. No significant model could be obtained (one principal component, $R^2 = 0.56$, $Q^2 = 0.080$, CV-ANOVA: $p = 0.33$). Further, when including both FM and CON in the analysis, the model was not significant (one principal component and one orthogonal component, $R^2 = 0.50$, $Q^2 = -0.027$, CV-ANOVA: $p = 1$). These two models confirm that BMI had no effect on the significant proteoforms identified in any of the MVDA models.

Discussion
In this exploratory proteomic study, the major results were:

- Systemic differences between FM and CON were found in proteins involved in inflammatory, immunity, and metabolic processes.
- Pain intensity, sensitivity (PPT), and psychological distress in FM had associations with specific plasma proteins mainly involved in blood coagulation and processes of metabolism, inflammation, and immunity.

By analyzing the plasma proteome pattern of FM and CON using multivariate statistics and functional protein interaction network, significant differences in proteins involved in immunity, blood coagulation, metabolic, and inflammatory processes were found. These processes, among others, were also found in our previous study investigating the plasma proteome profile in women with CWP (mainly FM) compared to healthy controls. Ramirez-Tejero et al. found upregulated levels of several proteins involved in acute phase response, coagulation cascade, and the complement system, similar to the identified processes in this present study. Systemic differences in inflammatory proteins have also been found in farmers with musculoskeletal disorders. Studies of other proteome profiles in FM, e.g., CSF, have additionally shown proteins involved in inflammatory response. It is well known that there is interplay between the blood coagulation cascade and the complement system, and during inflammation, both these processes are highly active. Therefore, it is not surprising that these processes are identified in the networks, both regarding the disease state (comparing FM and CON) but also when clinical pain characteristics are evaluated. Even though not the exact same proteins are found to
be altered in this study compared to earlier studies, they are still involved in the same type of biological processes such as immunity, blood coagulation, metabolic, and inflammatory processes, which may overall point towards an inflammatory state among FM.

The most important proteoforms (with highest VIP and p(corr)) that were able to separate FM and CON, were downregulated proteoforms of Ig kappa chain C region, complement C-4B (fragment), fibrinogen alpha chain (fragment), and upregulated proteoforms of serotransferrin, alpha-2-antiplasmin, and haptoglobin (Table 2, Fig. 1). One proteoform of Ig kappa chain C region was downregulated, which partly confirms our previous results in the CWP cohort, where one of two proteoforms of Ig kappa chain C region were downregulated, however not the same proteoforms27. Further, several proteoforms of fibrinogen alpha chain (fragment) were downregulated. These proteoforms were not found significant in our previous study comparing CWP and CON27, but one (spot number 9106 with highest VIP and p(corr)) was found downregulated and associated with pain intensity in CWP28. Complement C-4B is part of the complement system and has its activity via the classical pathway. Two proteoforms were found significant, one upregulated (spot number 7101) and one downregulated (spot number 8101). The discrepancy in alteration of these proteoforms could be due to post-translational

| Spot number | Protein name | Accession number | VIPpred | p(corr) | FM median OD (interquartile range) | CON median OD (interquartile range) | Fold change FM versus CON |
|-------------|--------------|-----------------|---------|---------|-------------------------------------|-------------------------------------|-------------------------|
| Normal distress (HADS < 14) | | | | | | | |
| 1207 | Alpha-2-HS-glycoprotein | P02765 | 2.02 | −0.70 | 308 (847) | 579 (998) | 0.53 |
| 1205 | Alpha-2-HS-glycoprotein | P02765 | 1.96 | −0.69 | 1,225 (1,883) | 1,041 (1,830) | 1.18 |
| 3301 | Vitamin D-binding protein | P02774 | 1.64 | −0.57 | 2,511 (2,182) | 2,787 (2,446) | 0.90 |
| 1316 | Alpha-2-HS-glycoprotein | P02765 | 1.61 | −0.56 | 153 (429) | 216 (274) | 0.71 |
| 2304 | Vitamin D-binding protein | P02774 | 1.52 | −0.53 | 887 (705) | 1,247 (854) | 0.71 |
| 7205 | Fibrinogen beta chain | P02675 | 1.46 | −0.51 | 777 (353) | 847 (278) | 0.92 |
| 2406 | Alpha-2-antiplasmin | P08697 | 1.44 | −0.50 | 1,054 (763) | 1,114 (1,065) | 0.95 |
| 5405 | Hemopexin | P02790 | 1.33 | −0.46 | 2,014 (680) | 1,868 (765) | 1.08 |
| 6507 | C4b-binding protein alpha chain | P04003 | 1.32 | −0.46 | 381 (182) | 375 (277) | 1.02 |
| 9015 | Serum amyloid A-4 protein | P35542 | 1.31 | −0.46 | 628 (869) | 887 (620) | 1.29 |
| 6104 | Ficolin-3 | O75636 | 1.24 | −0.43 | 425 (196) | 449 (168) | 0.95 |
| 5706 | Complement C1r subcomponent | P00736 | 1.21 | −0.42 | 99 (84) | 133 (118) | 0.74 |
| 1202 | Alpha-2-HS-glycoprotein | P02765 | 1.16 | −0.41 | 1,373 (1,023) | 910 (1,409) | 1.51 |
| 6109 | Unidentified | Unknown | 1.08 | −0.38 | 88 (94) | 71 (107) | 1.23 |
| 1310 | Kininogen-1 | P01042 | 1.05 | −0.37 | 199 (130) | 226 (125) | 0.88 |
| 7311 | Unidentified | Unknown | 1.05 | −0.37 | 203 (127) | 220 (116) | 0.92 |
| 7002 | Haptoglobin | P00738 | 1.02 | −0.36 | 79 (210) | 72 (226) | 1.09 |
| Mild distress (HADS 15–20) | | | | | | | |
| 3501 | Alpha-1B-glycoprotein | P04217 | 1.08 | +0.38 | 2,822 (726) | 3,151 (576) | 0.90 |
| Moderate distress (HADS > 21) | | | | | | | |
| 1203 | Alpha-2-HS-glycoprotein | P02765 | 1.51 | +0.53 | 1,546 (1,218) | 1,702 (1,363) | 0.91 |
| 9406 | Fibrinogen alpha chain | P02671 | 1.36 | +0.48 | 1,505 (1,762) | 1,844 (1,177) | 0.82 |
| 3010 | Apolipoprotein A-I | P02647 | 1.35 | +0.47 | 64,643 (16,886) | 66,242 (17,870) | 0.98 |
| 9503 | Fibrinogen alpha chain | P02671 | 1.24 | +0.43 | 2,844 (2,571) | 3,283 (2,001) | 0.87 |
| 9501 | Fibrinogen alpha chain | P02671 | 1.21 | +0.42 | 3,688 (2,915) | 3,894 (2,478) | 0.95 |
| 9409 | Fibrinogen beta chain | P02675 | 1.12 | +0.39 | 5,127 (2,617) | 5,497 (2,201) | 0.93 |
| 8509 | Fibrinogen alpha chain | P02671 | 1.11 | +0.39 | 2,802 (2,207) | 2,736 (1,895) | 1.02 |
| 9007** | Ig kappa chain C region | P01834 | 1.01 | +0.35 | 1,167 (1,888) | 1,883 (2,049) | 0.62 |

Table 5. Plasma proteins associated with psychological distress in FM. Proteins with a VIP > 1 associated with psychological distress in FM. Spot numbers refers to equal numbers in Fig. 7 and marked proteins spots in supplementary Figure S1 and Table S1. Accession numbers are according to the protein data base UniProt (www.uniprot.org). Variable influence on projections (VIP) indicates the importance of the regressor, the higher value, the more important for the model. A VIP > 1 is considered as a significant protein. p(corr) is shown and is the correlation coefficient of each variable (protein) for the model. A positive p(corr) for a variable indicates a positive multivariate correlation with the Y-variable (HADS total), and a negative p(corr), indicates a negative multivariate correlation with psychological distress in FM. The median quantified intensity (optical density, OD) from each group is shown in the table as a comparison. As descriptive values, protein fold change in FM compared to CON is reported. Please note that fold change is a univariate measure and do not necessarily correspond to p(corr); i.e. a positive fold change (FM > CON) is not automatically equal to a positive p(corr). The CON group is not included in the OPLS analysis. **Indicates shared proteoform with the model of group differences in FM and CON.
modification causing the pI to shift (which is seen in the location of the proteoforms in Supplementary Figure S1) or other modification which could affect the expressed levels; however, it might also be due to the disease state, which needs to be confirmed in more in-depth analysis. These two proteoforms were found upregulated in the model of CON and HADS total in our previous study28.

Regarding the upregulated proteins with highest VIP and p(corr), this study partly confirms our previous findings showing upregulated proteoforms of alpha-2-antiplasmin and haptoglobin. Though, in our previous study they were expressed as other proteoforms and as haptoglobin beta chain27. Serotransferrin was also confirmed in this study by two upregulated proteoforms; however, in the CWP cohort, another proteoform was found decreased27. Increased levels of specific serotransferrin proteoforms have been found in plasma from farmers with musculoskeletal disorders35 and in whole saliva from FM compared to controls29, which are in line with the findings in this study. Serotransferrin is known to be responsible for binding and transporting iron in the blood. Iron has been suggested to be involved in the pathophysiology behind FM37 via its acting as a cofactor in the production of the neurotransmitters dopamine and serotonin. Further, haptoglobin was also among the proteoforms with the highest VIP and p(corr). Haptoglobin is primarily produced in the liver and is a main transport of hemoglobin in the circulation. It is also classified as an acute-phase protein, due to its substantial increase during inflammation. It has been proposed that IL-6, among other cytokines released by macrophages and monocytes, affects hepatic cells to produce and, as a result, increase the haptoglobin concentration in the circulation38,39. In this cohort, we previously found increased plasma levels of the proinflammatory cytokines IL-6, IL-2, TNF-α, IP-10, and eotaxin40, which also have been seen in other studies of FM11,41–43. It is tempting to speculate that the increase in IL-6 specifically could explain the increase of two of the proteoforms of haptoglobin seen in FM in this cohort. However, it does not explain the decrease of another proteoform, which is the C-terminal part of haptoglobin (haptoglobin beta chain) that was seen in the model of pain intensity in FM. Increased levels of haptoglobin have been found in other studies investigating FM/CWP25,31, neuropathic pain21, and farmers with musculoskeletal disorders35. Haptoglobin’s involvement in FM needs to be further evaluated in additional studies. Overall, this present study further confirms that there is a possible alteration in proteins closely involved in the immune system, inflammation, metabolic, and blood coagulation processes in FM.

As expected and intended, the pain intensity was significantly higher in FM compared to CON (Table 1). In the score plot of FM and pain intensity, a within-group separation could be seen, which is based on the divided pain intensity categories (Fig. 3). By combining the score and loading plot, several proteins were associated with respective pain intensity category. Overall, the proteins that were associated with pain intensity were proteins involved in three different processes of immune response, blood coagulation, and protein metabolic process. These results confirm parts of our previous analysis of plasma proteins associated with pain intensity in CWP28, where ceruloplasmin, haptoglobin, different forms of fibrinogen (gamma and alpha chain), and clusterin were found altered. Pain intensity has been correlated to proteins involved in metabolic, stress, contractile, and inflammatory processes in muscle biopsies of the trapezius from the same CWP cohort44. Further, metabolic proteins were found in muscle biopsies from females with trapezius myalgia25. Overall, a vast majority of proteins

Figure 8. Pathway analysis of plasma proteins associated with psychological distress in FM. Functional protein network analysis of significant proteins associated with psychological distress in FM. The STRING version 11 was used to create the network analysis (https://string-db.org/). FCN3, Ficolin-3, A1BG Alpha-1-B-glycoprotein, HP Haptoglobin, FGB Fibrinogen beta chain, FGA Fibrinogen alpha chain, CBPA C4b-binding protein alpha chain, SERPINF2 Alpha-2-antiplasmin, KNG1 Kininogen-1, APOA1 Apolipoprotein A-1, AHSG Alpha-2-HS-glycoprotein, C1R Complement C1r subcomponent, HPX Hemopexin, SAA4 Serum amyloid A-4 protein, GC Vitamin D-binding protein.
associated with pain intensity belonged to metabolic processes in these and this present study. It seems that there is a specific metabolic protein profile in FM/CWP that is associated with pain intensity, which could be detected not only in peripheral muscle tissue but also systemically in FM.

Clusterin is suggested to be involved in inflammation due to its involvement in complement activation, apoptosis, and its ability to interact with immune cells such as macrophages and dendritic cells. Interestingly, the proteoform of clusterin (spot number 1107, Table 3) associated with severe pain intensity was also found to be decreased in the CWP cohort. Decreased level of clusterin has been found in serum from patients with erosive hand osteoarthritis, and negatively correlated with pain. Ceruloplasmin is one of the major acute-phase proteins that increases during inflammation and is responsible for the copper ion transport in the blood. One downregulated proteoform of ceruloplasmin was associated with moderate pain intensity (spot number 3810, Table 3). Upregulated levels of ceruloplasmin, however, expressed as another proteoform, and associated with pain intensity in CWP, were found in our previous study. These two different proteoforms of ceruloplasmin were among the proteins with the highest VIP and p(corr) in each regression model from the respective studies. Further, elevated levels of ceruloplasmin have previously been found in FM patients compared to controls. We also found several altered proteoforms of ceruloplasmin in CWP compared to controls. Even though there are different proteoforms and/or total protein that were differentially altered in these studies, it seems that ceruloplasmin is involved in FM/CWP, and especially associated with pain intensity, which is one of the main clinical facets of FM. The function and influence of the specific proteoforms and downregulation of ceruloplasmin in this study need to be further elucidated in future studies. However, we cannot neglect that this protein shows up in several studies and might be involved in the pathophysiology behind FM. Several different forms of fibrinogen (alpha and beta) were upregulated and associated with pain intensity (Table 3), as in the CWP cohort. Increased levels of blood coagulation proteins, e.g., fibrinogen, thrombin, have earlier been found in patients with chronic fatigue syndrome and/or FM. It was also one of the major proteins, together with haptoglobin, that was elevated in the FM studied by Ramirez-Tejero et al. Our results further

Figure 9. Venn diagram of shared proteoforms and proteins. (a) Venn diagram showing shared proteoforms between all models. Group group differences FM and CON, PPT PPT in FM, HADS Psychological distress in FM, VAS pain intensity in FM. Numbers prior protein name refer to unique spot numbers, while UniProt accession number for each protein is indicated in parenthesis. (b) Upper Venn diagram shows shared proteins between all four MVDA models. Venn diagrams below shows the comparison between two models individually, displaying the total number of shared proteins between respective models. UniProt accession number is indicated in parenthesis. The Venn diagrams were created in R using the Venndiagram package.
confirm that a specific protein profile for pain intensity in FM exists and that there is an increased metabolic and immunity process and decreased inflammatory process since several of the significant proteins that were involved in inflammation were downregulated in FM.

PPT is a semi-objective measurement of pain sensitivity, and several studies have shown reduced PPT in chronic pain conditions, especially FM/CWP compared to controls. In agreement with this, we found that PPT was significantly reduced in the FM group compared to CON (Table 1). When investigating the plasma proteins related to PPT in FM, a within-group separation of the most important proteins was seen. The network analysis showed a distinct inflammatory profile, where elevated proteoforms of angiotensinogen, alpha-2-HS-glycoprotein, fibrinogen beta chain, and alpha-1-antitrypsin were associated with very low PTT in FM (Table 4).

To the best of our knowledge, this is the first study to investigate the correlation between PPT and plasma proteins in FM. However, decreased PPT has been correlated with specific muscle proteins involved in stress, metabolic processes, and inflammation, in women with CWP compared to healthy controls. Further, from the same CWP cohort, PPT was found negatively correlated with a specific cytokine/chemokine profile in CWP and CON. Proteoforms of angiotensinogen and alpha-1-antitrypsin in FM patients have been altered in neuroendocrine pain patients compared to controls. Our study further confirms that specific plasma proteins involved in immunity/inflammation are associated with reduced PPT in FM.

We found significantly higher HADS total scores in FM compared to CON (Table 1). A within-group separation in FM was seen based on reported levels of psychological distress (Fig. 7). The majority of proteins associated with psychological distress in FM were proteins involved in acute-phase response, coagulation, and immunity process (Fig. 8). Previously, we have investigated the plasma proteome and association with psychological distress in CWP. There, we found hemopexin, complement factor B, and clusterin, among others, to be positively associated with increased psychological distress in CWP. Different proteoforms of hemopexin were found in this study compared to the CWP cohort, however all proteoforms of hemopexin have been found in farmers with musculoskeletal disorder. In addition, several proteomic studies of major depressive disorder have been conducted, revealing proteins to be involved in similar processes presented in this study, mainly acute-phase, blood coagulation, and immunity. These studies indicate that the immune system and its proteins might be affected by elevated depression. However, it is important to stress that none of the FM patients in this cohort were clinically classified with major depression and/or anxiety, and that could therefore be one reason for the different expression of proteoforms in the aforementioned studies. Even though we were not able to confirm the same results in this FM group, as in the CWP cohort, the same type of processes (immunity and blood coagulation) were identified. This study further confirms that there is a specific plasma protein pattern in FM associated with psychological distress, which in several aspects is similar to those seen in other patient groups experiencing depression and/or anxiety.

Four proteoforms were shared in the models of group differences and PPT in FM, and one proteoform was shared in the models of group differences and HADS total in FM (Fig. 9a). The discriminating proteoforms between the FM and the control group were also associated with pain sensitivity or moderate psychological distress in FM. Different proteoforms and alterations of fibrinogen beta chain were found in all MVDA models, and hemopexin was shared between the three clinical models. One explanation to the shared proteins/proteoforms may be that the clinical variables (pain intensity, pain sensitivity, HADS total, BMI, and age) were significantly correlated and hence confounded each other. However, a PCA of these variables in FM was not significant, which does not support such an explanation. These re-occurring proteins might reflect processes that are of importance and involved in the clinical aspects of FM. It is evident that not only central mechanisms are involved in FM, but also that peripheral factors play an important role in the mechanisms underlying FM.

Even though plasma has several advantages and is routinely used in clinical settings to analyze, e.g., acute-phase proteins, few studies have focused on the plasma proteome in chronic pain conditions, specifically FM. Several limitations exist when analyzing the plasma proteome. Plasma is a challenging fluid to study since it contains a high dynamic range of proteins with different abundance. Depending on the choice of analyzing technique and its sensitivity, several orders of magnitude of both high and low abundant proteins can be studied, but the full dynamic range of plasma proteins is still challenging to analyze using proteomics. To reduce complexity, fractionation could be used (either protein or peptide level). Another common method to reduce complexity is to remove the top abundant proteins in plasma. In this study, we have chosen to deplete two of them, albumin and immunoglobulin G, which might have eliminated potential protein candidates, but also visualized other masked proteins of interest at a similar molecular weight and/or pI. Two-dimensional gel electrophoresis is a useful technique not only to visualize a protein’s molecular weight and pI and, therefore, different proteoforms but also post-translational modifications. This has been shown in this study and previous ones to be of importance when comparing group differences and clinical characteristics among FM/CWP. For future considerations, retrieval of blood samples during a specific time point of the day must be standardized, which was not done in this study. In a recent plasma proteomic study, it has been shown that several plasma proteins have a diurnal variation, especially immunity proteins involved in the complement system and inflammatory proteins. We have excluded patients with severe comorbidities/disorders since an important part of this project was an exercise intervention (reported elsewhere). Nevertheless, as reported in Table 1, patients had higher psychological distress and BMI. Several studies have shown that an increased BMI could affect immunity proteins specifically complement system proteins. Therefore, we cannot exclude that the whole proteomic profile is influenced by BMI, especially the inflammatory proteins seen in the different models. Hence, BMI has been shown to be associated with several clinical symptoms in FM, and to investigate if BMI is involved in the pathophysiology of FM, future studies with a large number of subjects including FM with normal BMI and high BMI is necessary.

In this study, the ACR 1990 classification criteria for FM was used, and not the newer criteria from 2010/2011 or 2016. Some of the FM patients would perhaps not be diagnosed with FM if the newer criteria were used. In future studies, the ACR 1990 and 2010/2011 or 2016 criteria should be used in studies analyzing biomarkers in
were available for analysis in this study. The ACR 1990 classification criteria were used to assess FM diagnosis. Participants started in 2010, and data collection ended at all sites in 2013. Samples from 30 FM patients and 32 CON participants were used for analysis. The ACR 1990 classification criteria were the best recognized at that time point. Further, the inclusion criteria for both FM patients and healthy CON were to be of working age (20–63 years). For the CON group, good health and no current pain should be present. Exclusion criteria for both groups were high blood pressure (> 160/90 mmHg), osteoarthritis in the hip or knee, other severe somatic or psychiatric disorders, primary causes of pain other than FM, high consumption of alcohol (audit > 6), participation in a rehabilitation program within the past year, regular resistance exercise or relaxation therapy twice a week or more, inability to understand or speak Swedish, and not being able to refrain from analgesics, NSAID, or hypnotics for 48 h prior to examinations. Severe somatic disorders were, for instance, such as rheumatic disorders (e.g., Rheumatoid arthritis, Systemic lupus erythematosus), neurological diseases (e.g., Multiple sclerosis, Amyotrophic lateral sclerosis), diabetes mellitus, and cardiovascular diseases. Psychiatric diseases excluded were, e.g., major depressive disorder, severe anxiety disorders, and psychosis.

The study was conducted at three centers in Sweden (Gothenburg, Linkoping, and Stockholm) and in accordance with the Helsinki Declaration and Good Clinical Practice. The Ethical Review Board at Karolinska Institutet in Stockholm approved the study (Dnr: 2010/1121-31/3). All participants received verbal and written information about the study, and after that, written informed consent was obtained from all the participants in this study. All participants were compensated economically for their participation in the study.

Background data, questionnaires, and pain characteristics. All participants answered questionnaires, including general background data as age (years), weight (kg), height (m), and body mass index (BMI; kg/m²) was calculated. For FM patients, the number of tender points was recorded after manual palpation by an experienced examiner to verify the ACR 1990 diagnosis of FM, and the pain duration (years) was recorded. For all participants, pain intensity (whole-body) present for the past seven days was recorded using VAS (0–100). The reported VAS score has in this study been divided into the following categories: mild (5–44), moderate (45–74), and severe (75–100) pain intensity. To assess the severity of FM, the FIQ was used. It consists of 10 subscales that are disease-specific regarding disabilities and symptoms and range from 0 to 100. In this study, the FIQ total is presented and is the mean score of all ten subscales. A high score indicates a lower health status.

The validated Swedish version of the HADS was used to assess anxiety and depression. Each subscale of HADS, HADS-anxiety and HADS-depression, consist of seven items and scores from 0 to 21. In this study, the results from the two subscales were summarized and presented as the total score of HADS, hence, to indicate psychological distress. The total HADS score was divided into three categories according to the original case definition based on the separate anxiety and depression scale: normal psychological distress (< 14), mild psychological distress (15–20), and moderate psychological distress (> 21).

PPT were measured by a trained examiner, using an electronic pressure algometer (Somedic SenseLab AB, Sosdala, Sweden). The probe area was 1 cm², and the algometer was held perpendicularly to the skin area and pressed with a speed of approximately 50 kPa/s. Before the start of the measurement, the participants were familiarized with the testing procedure and instructed to mark their PPT during the experiment by pressing on a button as soon as the sensation of “pressure” changed to “pain.” When pushing the stop button or when maximum pressure was reached (1,500 kPa), the examiner removed the algometer, and the pressure stopped immediately. Algometry was performed on eight of 18 tender points defined by ACR criteria from 1990 over the following sites: bilaterally over the supraspinatus muscle (at origins above the scapula spine near the medial border), the lateral epicondyle (2 cm distal to the epicondyles), over the gluteus maximus (in upper outer quadrants of buttocks in anterior fold of muscle), and inside of the knee (at the medial fat pad proximal to the joint line). In this present study, a mean value of the PPT from all eight sites was used in the background data and MVDA.
has been divided into three categories: PPT 0–200, PPT 201–300, and PPT 301–400. PPT 0–200 is classified as very low pain sensitivity in the statistical analysis.

Blood collection. Venous blood samples were collected from each participant with a Vacutainer (BD Vacutainer Eclipse Blood Collection Needle, BD Diagnostics, Becton, Dickinson, and Company, New Jersey, USA) in 10 mL K₂EDTA tubes (BD Vacutainer Plus Plastic K₂EDTA Tubes, BD Diagnostics). The plasma was retrieved by centrifuging the blood samples for 30 min 1,500 x g at RT immediately after collection. The plasma fraction was removed to a new tube before aliquoted and stored in − 86 °C until analysis.

Proteomics. Plasma sample preparation. The details for sample preparation have been described in previous studies.²⁸ ProteoPrep Immunoaffinity Albumin and Immunoglobulin G depletion kit was used to deplete the top two abundant proteins in plasma, albumin, and immunoglobulin G (Sigma-Aldrich Co, St Louis, MO, USA). Forty µl of plasma from each subject was added to separate columns and depletion was achieved according to the manufacturer’s protocol. The samples were desalted with PD-10 columns (GE Healthcare, Little Chalfont, UK) and lyophilized. The lyophilized plasma proteins were resolved in urea sample buffer (8 M urea, 2% 3-((3-Cholamidopropyl) dimethylammonio)-1-propanesulfonate hydrate (CHAPS) (w/v), 0.3% Dithiothreitol (DTT), 0.5% Phamalyte 3-10 (w/v), bromophenol blue), and total protein concentration was measured with 2-D Quant Kit (GE Healthcare) according to manufacturer’s instructions, as described in previous studies.²⁸

2-DE. A random sequence generator (www.random.org) was used to randomize the samples before run. The procedure of 2-DE has been described in detail in previous studies.²⁸ Hundred µg of total protein was applied to 18 cm Immobiline DryStrip gel pH 3–10 non-linear (GE Healthcare) and run in the Ettan IEF System (GE Healthcare) for 38,000 Vhs overnight. Each IEF strips was stored at ~ 86 °C until run in second dimension. Prior run in second dimension, the IEF strips were equilibrated twice for 15 min in sodium dodecyl sulfate (SDS) equilibrium buffer (6 M urea, 4% SDS (w/v), 30.5% glycerol (w/v), 0.5 M Trizma-HCl), containing first 1% DTT (w/v) to reduce the disulfide bonds and secondly with 4.5% iodoacetamide (w/v) to alkylate sulf-hydryl groups and bromophenol blue for tracing. Second dimension was performed vertically on Ettan DALtix Electrophoresis Unit (Amersham Pharmacia Biotech, Uppsala, Sweden) according to the manufacturer’s protocol. The proteins from the IPG strips were transferred to pre-casted homogeneous 12.5% acrylamide gels (GE Healthcare), and initially run for 1 h at 80 V, 10 mA/gel, followed by 600 V, 40 mA/gel until the bromophenol blue line reached the bottom of the gel (approx. 6 h). Immediately after run, each gel was placed in fixative solution (10% methanol (v/v), 7% acetic acid (v/v)) overnight. The gels were then fluorescently stained with SYPRO Ruby (Bio-Rad Laboratories, Hercules, CA, USA) overnight. Each gel was visualized using a charged coupled device camera (VersaDoc Imaging system 4,000 MP; BioRad Laboratories). 2-DE protein patterns were analyzed and quantified using the software PDQuest Advanced version 8.0.1 (Bio-Rad Laboratories). The amount of protein in a spot was assessed as background-corrected optical density, integrated over all pixels and expressed as optical density. Quantified and matched proteins needed to be present in at least 50% in one of the groups to be eligible for further multivariate data analysis, as described in previous studies.²⁷

In-gel digestion by trypsin and protein identification. Protein spots of interest were either identified by spot matching to previously identified plasma proteins or by in-gel digestion using mass spectrometry as follows. Briefly, the spots were excised from the gel and de-stained with 50% acetonitrile (ACN) in 25 mM ammonium bicarbonate (v/v), dehydrated with 100% ACN, and dried in SpeedVac before digested with trypsin (1:20 trypsin:protein, Promega Biotech AB, Nacka, Sweden) at 37 °C overnight. Supernatants were then transferred into a new tube, and a second extraction step in 5% trifluoroacetic acid in 50% ACN on shaking for 4 h was performed. The two supernatants were then pooled, dried in SpeedVac and stored at -20 °C until analyzed with mass spectrometry (MS). The tryptic peptides were analyzed using a nano liquid chromatography system (EASY-nLC, Thermo Scientific, Waltham, MA, United States) with a C18 column (100 mm x 75 µM, Agilent technologies, Santa Clara, CA, USA) coupled to an LTQ Orbitrap Velos Pro MS (Thermo Scientific). Mobile phase (buffer A) consisted of 0.1% formic acid (v/v) in dH₂O and peptides were separated using a linear gradient increasing from 2 to 90% ACN including 0.1% formic acid (buffer B), for 30 min with a flow rate of 300 nL/min. MS1 scan was performed with a mass range of 380–2000 m/z in positive mode, and the resolution was set to 30,000. In MS2 scan (MS/MS), the top 20 peaks from the full scan were selected for fragmentation. Peaks with + 1 charge state were rejected, and dynamic exclusion was 30 s. Acquired raw files were analyzed with the software MaxQuant (version 1.5.8.3) against the human Swissprot/UniProt database (downloaded April 2018), with the following parameters; enzyme digestion with trypsin, the maximum number of missed cleavages 2, minimum peptide length 7, maximum peptide mass was 4,600 Da, parent ion mass tolerance 4.5 ppm, fragment ion mass tolerance 0.5 Da. Fixed modification was carboxymethylation of cysteine, and variable modifications were oxidation of methionine and N-terminal acetylation. Protein false discovery rate (FDR) was set to < 1%, and a minimum of 1 unique peptide was needed to be considered as identified.

Statistics. Background data were tested for normality, and the non-parametric Mann–Whitney U test was used to calculate group differences with SPSS version 24 (International Business Machines Corporation (IBM), Armonk, New York, USA). A p value ≤ 0.05 was considered significant. Data are presented as median and inter-quartile range if not stated otherwise. MVDA is often used when large omics data are handled, and in this study, we have investigated multivariate correlations between quantified plasma proteins and group belonging (FM and CON) with the statistical model
OPLS-DA using SIMCA P+ version 15 (Umetrics, Umeå, Sweden). The OPLS-DA is a supervised modeling method and is used to detect variables able to discriminate between FM and CON. Regressions were analyzed between the clinical variables pain intensity, PPT, psychological distress, and quantified plasma proteins in FM, respectively, using OPLS modeling. The respective clinical variable was used as a single y-variable, and x-variables were quantified plasma proteins in FM. OPLS modeling has the ability to detect systemic variation in x-variables that either correlates or not (orthogonal) to y-variables. Both the OPLS-DA and OPLS models were performed in two steps, as described in previous studies. All variables were mean-centered and scaled to unit variance (UV scaling) and log-transformed if necessary. An initial principal component analysis (PCA) was created to investigate possible outliers in the data set. One of the control samples was marked as a critical outlier by Hotelling’s T², and after reviewing the data, it was removed from further analysis, resulting in 31 controls. All quantified plasma proteins (regressors) were in the first step included in the analysis and significant proteins with a variable influence on projection (VIP) value ≥ 1 with a jack-knifed 95% confidence interval not including zero were selected for a second new regression model and presented in the results. VIP is a value that indicates the relevance of each x-variables pooled over all dimensions and y-variables, e.g., which x-variables that best explain Y; in models with one predictive component and one or several orthogonal components VIP predictive is used. The higher the VIP value, the more important regressor for the model. Further, analysis of variance of cross-validated predictive residuals (CV-ANOVA) was used to validate the significant level of each model (p ≤ 0.05 was regarded as a significant model). R² describes the goodness of fit, which is the fraction of the sum of squares of all the variables explained by a principal component. It is a measure of how well the model is explained by the data set. A cross-validated Q² describes the goodness of prediction of the model, which is the fraction of the total variation of the variables that can be predicted by a principal component. This has been well described in our previous studies. Each x-variable (proteins) is expressed as loadings in a loading plot and has a value ranging from –1 to +1; note that this is a multivariate correlation coefficient. The larger the loading, the more impact on the model’s principal components. p(corr) is the x variable loadings scaled as a correlation coefficient and is ranging from –1 to +1. The closer to absolute p(corr) to 1, the stronger is the correlation. The p(corr) is the x variable loadings scaled as a correlation coefficient and is ranging from –1 to +1. The closer to absolute p(corr) to 1, the stronger is the correlation. The score plot shows the observations (FM or CON), and by combining the score plot and loading plot, important variables can be coupled to specific observations or within-in group separations. The described parameters necessary to evaluate MVDA modeling (R², Q², number of principal/orthogonal components, CV-ANOVA, and p value) are presented as suggested guidelines by Wheelock and Wheelock.

Confounding factors on significant proteoforms and clinical variables using OPLS and PCA. To adjust for a potential confounding effect of BMI on significant proteoforms, additional OPLS models were analyzed. The first model included FM and all significant proteoforms from each clinical MVDA model as regressors and BMI as y-variable. The second OPLS model included FM and CON, the significant proteoforms from the OPLS-DA model (comparing group differences) as regressors and BMI as y-variable. The clinical variables were analyzed with a PCA, to investigate potential interactions between each variable.

Correlation matrices clinical variables and significant proteoforms. Spearman’s correlation matrices were calculated including the clinical variables VAS, PPT, HADS and significant proteoforms from respective OPLS models, using the R package Corrplot (version 0.84) (Supplementary Figures S2–S4).

Bioinformatics. Protein–protein association network analysis was created using the online data-base tool STRING version 11. Protein accession numbers (UniProt) from significant proteins from each MVDA model was entered in the search engine (multiple proteins) with the following parameters: Organism Homo sapiens, the maximum number of interaction was query proteins only, interaction score was set to medium confidence (green), gene fusion (red) and gene-co-occurrence (dark blue), and other interactions were text mining (yellow), databases (turquoise) and experimentally determined (pink). Predicted interactions were gene neighborhood represented by an edge visualized as a colored lined (type of interaction). Known interactions used were from curated databases (turquoise) and experimentally determined (pink). Venn diagrams and heatmap were created with the R software (version 3.6.1)/R studio (version 1.2.1335) with the packages VennDiagram (version 1.6.20) and heatmap2 included in gplots (version 3.0.1.1).

Received: 4 February 2020; Accepted: 10 July 2020
Published online: 27 July 2020

References
1. Gran, J. T. The epidemiology of chronic generalized musculoskeletal pain. Best Pract. Res. Clin. Rheumatol. 17, 547–561. https://doi.org/10.1016/s1521-6942(03)00042-1 (2003).
2. Queiroz, L. P. Worldwide epidemiology of fibromyalgia. Curr. Pain Headache Rep. 17, 356. https://doi.org/10.1007/s11916-013-0356-5 (2013).
3. Wolfe, F. et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the multicenter criteria committee. Arthritis Rheum. 33, 160–172. https://doi.org/10.1002/art.1780330203 (1990).
4. Wolfe, F., Walitt, B., Perrot, S., Rasker, J. J. & Hauser, W. Fibromyalgia diagnosis and biased assessment: sex, prevalence and bias. PLoS ONE 13, e0203755. https://doi.org/10.1371/journal.pone.0203755 (2018).
5. Okifuji, A., Bradshaw, D. H. & Olson, C. Evaluating obesity in fibromyalgia: neuroendocrine biomarkers, symptoms, and functions. Clin. Rheumatol. 28, 475–478. https://doi.org/10.1007/s10067-009-1094-2 (2009).

SCIENTIFIC REPORTS | (2020) 10:12508 | https://doi.org/10.1038/s41598-020-69422-z
6. Clauw, D. J. Fibromyalgia: an overview. Am. J. Med. 122, S3–S13. https://doi.org/10.1016/j.amjmed.2009.09.006 (2009).

7. Creed, F. A. review of the incidence and risk factors for fibromyalgia and chronic widespread pain in population-based studies. Pain 161, 1169–1176. https://doi.org/10.1097/PAIN.0000000000001819 (2020).

8. Wolfe, F. et al. 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin. Arthritis Rheum. 46, 319–329. https://doi.org/10.1016/j.semarthrit.2016.08.012 (2016).

9. Wolfe, F. et al. Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia. J. Rheumatol. 38, 1113–1122. https://doi.org/10.3899/jrheum.100594 (2011).

10. Wolfe, F. et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res. 62, 600–610. https://doi.org/10.1002/acr.20140 (2010).

11. Backryd, E., Tanum, L., Lind, A. L., Larsson, A. & Gordh, T. Evidence of both systemic inflammation and neuroinflammation in fibromyalgia patients, as assessed by a multiplex protein panel applied to the cerebrospinal fluid and to plasma. J. Pain Res. 10, 515–525. https://doi.org/10.2147/JPR.S296508 (2017).

12. Backryd, E., Tanum, L., Lind, A. L., Larsson, A. & Gordh, T. Evidence of both systemic inflammation and neuroinflammation in fibromyalgia patients, as assessed by a multiplex protein panel applied to the cerebrospinal fluid and to plasma. J. Pain Res. 10, 515–525. https://doi.org/10.2147/JPR.S296508 (2017).

13. Rodriguez-Pinto, I., Agmon-Levin, N., Howard, A. & Shoenfeld, Y. Fibromyalgia and cytokines.

14. Malatji, B. G.

15. Minerbi, A.

16. Backryd, E., Ghafouri, B., Carlsson, A. K., Olausson, P. & Gerdle, B. Multivariate proteomic analysis of the cerebrospinal fluid of patients with peripheral neuropathic pain and healthy controls—a hypothesis-generating pilot study. J. Pain Res. 8, 321–333. https://doi.org/10.2147/JPR.S82970 (2015).

17. Backryd, E. et al. High levels of cerebrospinal fluid chemokines point to the presence of neuroinflammation in peripheral neuropathic pain: a cross-sectional study of 2 cohorts of patients compared with healthy controls. Pain 158, 2487–2495. https://doi.org/10.1097/PAN.00000000000001061 (2017).

18. Lind, A. L. et al. CSF levels of apolipoprotein C1 and autotaxin found to associate with neuropathic pain and fibromyalgia. J. Pain Res. 12, 2875–2889. https://doi.org/10.2147/JPR.S215348 (2019).

19. Gerdle, B., Ghafouri, B., Ghafouri, N., Backryd, E. & Gordh, T. Signs of ongoing inflammation in female patients with chronic widespread pain: a multivariate, explorative, cross-sectional study of blood samples. Medicine 96, e6130. https://doi.org/10.1097/MD.00000000000129 (2017).

20. Olausson, P., Ghafouri, B., Backryd, E. & Gerdle, B. Clear differences in cerebrospinal fluid proteome between women with chronic widespread pain and healthy women—a multivariate explorative cross-sectional study. J. Pain Res. 10, 575–590. https://doi.org/10.2147/JPR.S125667 (2017).

21. Olausson, P. et al. Protein alterations in women with chronic widespread pain—an explorative proteomic study of the trapezius muscle. Sci. Rep. 5, 11894. https://doi.org/10.1038/srep11894 (2015).

22. Hadrevi, J., Ghafouri, B., Larsson, B., Gerdle, B. & Hellstrom, F. Multivariate modeling of proteins related to trapezius myalgia, a comparative study of female cleaners with or without pain. PLoS ONE 8, e73285. https://doi.org/10.1371/journal.pone.0073285 (2013).

23. Wåhlén, K., Ghafouri, B., Ghafouri, N. & Gerdle, B. Plasma protein pattern correlates with pain intensity and psychological distress in women with chronic widespread pain— a case-control study. J. Psychosom. Res. 80, 155–155. https://doi.org/10.1016/j.jpsychores.2016.11.005 (2016).

24. Stensson, N., Ghafouri, B., Gerdle, B. & Ghafouri, N. Alterations of anti-inflammatory lipids in plasma from women with chronic widespread pain and healthy controls. Lipids Health Dis. 16, 112. https://doi.org/10.1186/s12944-017-0505-7 (2017).

25. Wåhlén, K., Ghafouri, B., Ghafouri, N. & Gerdle, B. Plasma protein pattern correlates with pain intensity and psychological distress in women with chronic widespread pain. Front. Psychol. 9, 2400. https://doi.org/10.3389/fpsyg.2018.02400 (2018).

26. Cregia, F. et al. Putative salivary biomarkers useful to differentiate patients with fibromyalgia. J. Proteom. 190, 44–54. https://doi.org/10.1016/j.jproteom.2018.04.012 (2019).

27. Bazzichi, L. et al. Detection of potential markers of primary fibromyalgia syndrome in human saliva. Proteom. Clin. Appl. 3, 1296–1304. https://doi.org/10.1002/prca.200900076 (2009).

28. Ramirez-Tejero, J. A. et al. Insight into the biological pathways underlying fibromyalgia by a proteomic approach. J. Proteom. 186, 47–55. https://doi.org/10.1016/j.jprot.2018.07.009 (2018).

29. Kadetoff, D., Lampia, J., Westman, M., Andersson, M. & Kosek, E. Evidence of central inflammation in fibromyalgia-increased cerebrospinal fluid interleukin-8 levels. J. Neuroimmunol. 242, 33–38. https://doi.org/10.1016/j.jneuroim.2011.10.013 (2012).

30. Ruggiero, V. et al. A preliminary study on serum proteomics in fibromyalgia syndrome. Clin. Chem. Lab. Med. 52, e207–e210. https://doi.org/10.1515/cclm-2014-0086 (2014).

31. Khoonsari, P. E. et al. Systematic analysis of the cerebrospinal fluid proteome of fibromyalgia patients. Journal of proteomics 190, 35–43. https://doi.org/10.1016/j.jprot.2018.04.014 (2019).

32. Ghafouri, B., Carlsson, A., Holmberg, S., Thelin, A. & Tagesson, C. Biomarkers of systemic inflammation in farmers with musculoskeletal disorders; a plasma proteomic study. BMC Musculoskeletal Disord. 17, 206. https://doi.org/10.1186/s12891-016-1059-y (2016).

33. Oikonomopoulou, K., Ricklin, D., Ward, P. A. & Lambris, J. D. Interactions between coagulation and complement— their role in inflammation. Semin. Immunopathol. 34, 151–165. https://doi.org/10.1007/s00281-011-0280-x (2012).

34. Orntanc, O., Sanli, A., Eryukel, R., Basaran, A. & Ankarali, H. Association between serum ferritin level and fibromyalgia syndrome. Eur. J. Clin. Nutr. 64, 308–312. https://doi.org/10.1038/ejcn.2009.149 (2010).

35. Raynes, J. G., Eagling, S. & McAdam, K. P. Acute-phase protein synthesis in human hepatoma cells: differential regulation of serum amyloid A (SAA) and haptoglobin by interleukin-1 and interleukin-6. Clin. Exp. Immunol. 83, 488–491. https://doi.org/10.1111/j.1365-2249.1991.tb05666.x (1991).

36. Jain, S., Gautam, V. & Naseem, S. Acute-phase proteins: as diagnostic tool. J. Pharm. Bioallied Sci. 3, 118–127. https://doi.org/10.4103/0975-7406.76489 (2011).

37. Ernberg, M. et al. Plasma cytokine levels in fibromyalgia and their response to 15 weeks of progressive resistance exercise or relaxation therapy. Mediat. Inflamm. 2018, 3985154. https://doi.org/10.1155/2018/3985154 (2018).

38. Hernandez, M. E. et al. Proinflammatory cytokine levels in fibromyalgia patients are independent of body mass index. BMC Res. Notes 3, 156. https://doi.org/10.1186/1756-0500-3-156 (2010).
42. Ghizal, F. D. S. K., Verma, N. & Mahdi, A. A. Evaluating relationship in cytokines level, Fibromyalgia Impact Questionnaire and Body Mass Index in women with Fibromyalgia syndrome. J. Back Musculoskelet. Rehabil. 29, 165–149. https://doi.org/10.3233/MBR-150610 (2016).
43. Zhang, Z. et al. High plasma levels of MCP-1 and eotaxin provide evidence for an immunological basis of fibromyalgia. Exp. Biol. Med. (Maywood) 233, 1171–1180. https://doi.org/10.3810/7712-328 (2008).
44. Olausson, P., Ghafouri, B., Ghafouri, N. & Gerdel, B. Specific proteins of the trapezius muscle correlate with pain intensity and sensitivity—an explorative multivariate proteomic study of the trapezius muscle in women with chronic widespread pain. J. Pain Res. 9, 345–356. https://doi.org/10.2147/JPR.S102275 (2016).
45. Cunin, P. et al. Clusterin facilitates apoptotic cell clearance and prevents apoptotic cell-induced autoimmune responses. Cell Death Dis. 7, e2215. https://doi.org/10.1038/cddis.2016.113 (2016).
46. Kropackova, T. et al. Lower serum clusterin levels in patients with erosive hand osteoarthritis are associated with more pain. BMC Musculoskelet. Disord. 19, 264. https://doi.org/10.1186/s12891-018-2179-3 (2018).
47. La Rubia, M., Rus, A., Molina, F. & Del Moral, M. L. Is fibromyalgia-related oxidative stress implicated in the decline of physical and mental health status? Clin. Exp. Rheumatol. 31, S121–127 (2013).
48. Berg, T., Berg, L. H., CouVARas, J. & Harrison, H. Chronic fatigue syndrome and/or fibromyalgia as a variation of antiphospholipid antibody syndrome: an explanatory model and approach to laboratory diagnosis. Blood Coagul. Fibrinolysis 10, 435–438. https://doi.org/10.1097/00001712-199910000-00006 (1999).
49. King, C. D. et al. Pressure pain threshold and anxiety in adolescent females with and without juvenile fibromyalgia: a pilot study. Clin. J. Pain 33, 620–626. https://doi.org/10.1097/AJP.0000000000000444 (2017).
50. Gerhardt, A. et al. Chronic widespread back pain is distinct from chronic local back pain: evidence from quantitative sensory testing, pain drawings, and psychometrics. Clin. J. Pain 32, 568–579. https://doi.org/10.1097/AJP.0000000000000300 (2016).
51. Ruland, T. et al. Molecular serum signature of treatment resistant depression. Psychopharmacology 233, 3051–3059. https://doi.org/10.1007/s00213-016-4348-0 (2016).
52. Lee, J. et al. Proteomic analysis of serum from patients with major depressive disorder to compare their depressive and remission statuses. Psychiatry Investig. 12, 249–259. https://doi.org/10.4306/pi.2015.12.2.249 (2015).
53. Törk, C. W. et al. Proteomic differences in blood plasma associated with antidepressant treatment response. Front. Mol. Neurosci. 10, 272. https://doi.org/10.3389/fnmol.2017.00272 (2017).
54. Anderson, N. L. & Anderson, N. G. The human plasma proteome: history, character, and diagnostic perspectives. Mol. Cell. Proteom. 1, 845–867. https://doi.org/10.1074/mcp20007-mcp200 (2002).
55. Jasim, H., Carlsson, A., Gerdel, B., Ernberg, M. & Ghafouri, B. Diurnal variation of inflammatory plasma proteins involved in pain. Pain Rep. 4, e776. https://doi.org/10.1097/PR9.0000000000000776 (2019).
56. Larson, A. et al. Resistance exercise improves muscle strength, health status and pain intensity in fibromyalgia—a randomized controlled trial. Arthritis Res. Ther. 17, 161. https://doi.org/10.1186/s13075-015-0679-1 (2015).
57. Sahebkhahtr, N. et al. Plasma proteomics analysis reveals dysregulation of complement proteins and inflammation in acquired obesity—a study on rare BMI-discordant monozygotic twin pairs. Proteome. Clin. Appl. 13, e1800173. https://doi.org/10.1002/peca.201800173 (2019).
58. Oberbach, A. et al. Combined proteomic and metabolomic profiling of serum reveals association of the complement system with obesity and identifies novel markers of body fat mass changes. J. Proteome Res. 10, 4769–4788. https://doi.org/10.1021/pr2005555 (2011).
59. Cordero, M. D. et al. Clinical symptoms in fibromyalgia are associated to overweight and lipid profile. Rheumatol. Int. 34, 419–422. https://doi.org/10.1007/s00296-012-2647-2 (2014).
60. Kim, C. H., Luedtke, C. A., Vincent, A., Thompson, J. M. & Oh, T. H. Association of body mass index with symptom severity and quality of life in patients with fibromyalgia. Arthritis Care Res. 64, 222–228. https://doi.org/10.1002/acr.20653 (2012).
61. Palatam, A. et al. Perceived exertion at work in women with fibromyalgia: explanatory factors and comparison with healthy women. J. Rehabil. Med. 46, 773–780. https://doi.org/10.2340/16501977-1843 (2014).
62. Boonstra, A. M., Schiphorst Preupper, H. R., Balk, G. A. & Stewart, R. E. Cut-off points for mild, moderate, and severe pain on the visual analogue scale for pain in patients with chronic musculoskeletal pain. Pain 155, 2545–2550. https://doi.org/10.1016/j.pain.2014.09.014 (2014).
63. Jensen, M. P., Chen, C. & Brugger, A. M. Interpretation of visual analogue scale ratings and change scores: a reanalysis of two clinical trials of postoperative pain. J. Pain 4, 407–414. https://doi.org/10.1016/s1526-9900(03)00716-8 (2003).
64. Hedlin, P., Hamme, M., Burckhardt, C. S. & Engstrom-Larsson, A. The Fibromyalgia Impact Questionnaire, a Swedish translation of a new tool for evaluation of the fibromyalgia patient. Scand. J. Rheumatol. 24, 69–75. https://doi.org/10.3109/03009749509909927 (1995).
65. Zigmund, A. S. & Snaith, R. P. The hospital anxiety and depression scale. Acta Psychiatr. Scand. 67, 361–370. https://doi.org/10.1111/j.1600-0447.1983.tb09716.x (1983).
66. Lisspers, J., Nygren, A. & Soderman, E. Hospital Anxiety and Depression Scale (HAD): some psychometric data for a Swedish sample. Acta Psychiatr. Scand. 96, 281–286. https://doi.org/10.1111/j.1600-0447.1997.tb10164.x (1997).
67. Lohmann, R., Ang, B. O., Gerdel, B. & Vixner, L. Psychometric properties of short form-36 health survey, EuroQol 5-dimensions, and Hospital Anxiety and Depression Scale in patients with chronic pain. Pain 161, 83–95. https://doi.org/10.1097/J.PAIN.0000000000000170 (2020).
68. Eriksson, L., Byrne, T., Johansson, E., Trygg, J. & Vikström, C. Multi- and Megavariate Data Analysis Basic Principles and Applications 3rd revised. (Umetrics Academy, MK3 Umetrics AB, Umeå, 2013).
69. Wheelock, A. M. & Wheelock, C. E. Trials and tribulations of ‘omics data analysis: assessing quality of SIMCA-based multivariate models using examples from pulmonary medicine. Mol. Biosyst. 9, 2589–2596. https://doi.org/10.1039/c3mb70194h (2013).
70. Dai, T. et al. Corrplot: visualization of a correlation matrix. R package version 0.84. https://cran.r-project.org/package=corrplot (2017). Accessed 11 June 2020.
71. Szklarczyk, D. et al. STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 47, D606–D613. https://doi.org/10.1093/nar/gkz1131 (2019).
72. R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing. https://www.R-project.org/ (2019). Accessed 05 August 2019.
73. Chen, H. VennDiagram: generate high-resolution Venn and Euler plots. R package version 1.6.20. https://CRAN.R-project.org/package=VennDiagram (2018). Accessed 30 August 2019.
74. Warnes, G. R. et al. Gplots: various R programming tools for plotting data. R package version 3.0.1. https://CRAN.R-project.org/package=gplots (2019). Accessed 30 August 2019.

Acknowledgements

Swedish Rheumatism Association, the Health and Medical Care Executive Board of Västra Götaland Region, ALF-LUA at Sahlgrenska University Hospital, Stockholm County Council (ALF), Magnus Bergvalls Foundation, Region Östergötland (ALF), Linköping University Hospital Research, Swedish Research Council (Nos.
K2013-52X-22199–01-3, K2015-99x-21874–05-4, 521–2010-2,893, and 2018–02,470), and Karolinska Institute Foundation. Open access funding provided by Linköping University.

**Author contributions**

B.Gh., B.Ge., M.E., E.K., K.M. contributed to the conception of the study. K.W. performed the experiments and analyzed all the data. K.W., B.Gh., B.Ge. drafted the manuscript. All authors contributed to the writing of the manuscript and approved the final version.

**Competing interests**

The authors declare no competing interests.

**Additional information**

**Supplementary information** is available for this paper at https://doi.org/10.1038/s41598-020-69422-z.

**Correspondence** and requests for materials should be addressed to K.W.

**Reprints and permissions information** is available at www.nature.com/reprints.

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

[Open Access] This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020